The preparation and biological characterization of a new HL91-derivative for hypoxic imaging on stroke mice

Applied Radiation and Isotopes

Volumn 68, Issue 9, 2010, Pages 1610-1615

  Hsia, Chien Chung ^a,b   Huang, Fu Lei ^b   Lin, Cheng Hsien ^b   Shen, Lie Hang ^b   Wang, Hsin Ell ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

HL91; Hypoxia; Stroke

Indexed keywords

BALB/C MICE; BIOLOGICAL CHARACTERIZATION; CELLULAR UPTAKE; ELECTROCAUTERY; HIGH YIELD; HL91; HYPOXIA; HYPOXIC CELLS; HYPOXIC CONDITION; HYPOXIC FRACTION; INTRAVENOUS INJECTIONS; LIPOPHILICITY; MIDDLE CEREBRAL ARTERY; MOUSE MODELS; N-OCTANOL; PARTITION COEFFICIENT; PASSIVE DIFFUSIONS; POST INJECTION; RADIOCHEMICAL PURITY; SMALL-ANIMAL; SPECT IMAGES; STANNOUS CHLORIDE; STROKE; TIME POINTS; UPTAKE MECHANISM;

ASSAYS; CARBON DIOXIDE; CHLORINE COMPOUNDS; HEALTH CARE; RADIOGRAPHY; TISSUE;

MAMMALS;

4,4,11,11 TETRAMETHYL 5,10 DIAZATETRADECANE 3,12 DIONEDIOXIME TC 99M; OXYGEN; PERTECHNETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; STANNOUS CHLORIDE; UNCLASSIFIED DRUG; UPENAZIME TC 99M; DIAGNOSTIC AGENT; OXIME; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 4,9 DIAZA 3,3,10,10 TETRAMETHYLDODECAN 2,11 DIONE DIOXIME; TECHNETIUM TC 99M 4,9-DIAZA-3,3,10,10-TETRAMETHYLDODECAN-2,11-DIONE DIOXIME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BAGG ALBINO MOUSE; BRAIN HYPOXIA; BRAIN TISSUE; CAUTERIZATION; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DESIGN; DRUG DETERMINATION; DRUG PURITY; DRUG SYNTHESIS; HELA CELL; ISOTOPE LABELING; LIPOPHILICITY; MIDDLE CEREBRAL ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; BRAIN; METHODOLOGY; SCINTISCANNING; STROKE; SYNTHESIS;

ANIMALS; BRAIN; HYPOXIA, BRAIN; ISOTOPE LABELING; MICE; MICE, INBRED BALB C; ORGANOTECHNETIUM COMPOUNDS; OXIMES; RADIOPHARMACEUTICALS; STROKE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79551683922     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2010.03.008     Document Type: Article

References (48)

1. Brizel D.M., Scully S.P., Harrelson J.M., Lagfield L.J., Bean J.M., Posnitz L.R., Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996, 56:941-943.
2. Ballinger J.R., Kee J.W.M., Rauth A.M. In vitro and in vivo evaluation of a technetium-99m-labelled 2-nitromidazole (BMS181321) as a marker of tumor hypoxia. J. Nucl. Med. 1996, 37:1023-1031.
3. Bederson J.B., Pitts L.H., Germano S.M., Nishimura M.C., Davis R.L., Bartkowski Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986, 17:1304-1308.
4. Benedek Angéla, Móricz Krisztina, Jurányi Zsolt, Gigler Gábor, Lévay György, Hársing László G., Mátyus Péter, Szénási Gábor, Albert Mihály Use of TTC staining for the evaluation of tissue injury in the early phases of reperfusion after focal cerebral ischemia in rats. Brain Res. 2006, 1116(1):159-165.
5. 64Cu-bis(thiosemicarbazonato)-glucose conjugate for hypoxia imaging. J. Nucl. Med. 2008, 49:1862-1868.
6. Brauers G., Archer C.M., Burke J.F. The chemical characterization of the tumor imaging agent 99mTc-HL91. Eur. J. Nucl. Med. 1997, 24:943.
7. Chapman J.D. Measurement of tumor hypoxia by invasive and noninvasive procedures: a review of recent clinical studies. Radiother. Oncol. 1991, 20:13-19.
8. Chapman J.D., Engelhardt E.L., Stobbe C.C., Schneider R.F., Hanks G.E. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother. Oncol. 1998, 46:229-237.
9. Chapman J.D., Zanzonico P., Ling C.C. On measuring hypoxia in individual tumors with radiolabeled agents. J. Nucl. Med. 2001, 42:1653-1655.
10. Cook J.R., Houston S., Barrington S.F., Fogelman I. Technetium-99m-labeled HL91 to identify tumour hypoxia: correlation with fluorine-18-FDG. J. Nucl. Med. 1998, 39:99-103.
11. Chapman J.D. Hypoxic sensitizers: implications for radiation therapy. N. Engl. J. Med. 1979, 301:1429-1432.
12. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 1998, 48:149-156.
13. Gandomkara M., Najafia R., Sadat Ebrahimib S.E., Shafieeb A., Babaeia M.H., Rabbanic M., Shabani G.A. Direct labelling of octreotide with 99mTc: effect of different concentration of reducing agents and amount of sodium pertechnetate on radiolabelling efficiency. Appl. Radiat. Isot. 2003, 58:361-364.
14. Guggenberg Elisabeth von, Penza Barbara, Kemmler Georg, Virgolini Irene, Decristoforo Clemens Comparison of different methods for radiochemical purity testing of [99mTc-EDDA-HYNIC-D- Phe1,Tyr3]-Octreotide. Appl. Radiat. Isot. 2006, 64:194-200.
15. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Nat. Cancer Inst. 2001, 93:266-276.
16. Horsman M.R. Measurement of tumor oxygenation. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42:701-704.
17. Hö ckel M., Schlenger K., Mitze M., Schäffer U., Vaupel P. Hypoxia and radiation response in human tumours. Semin. Radiol. Oncol. 1996, 6:3-9.
18. 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42:731-735.
19. Inna Serganova John, Humm Clifton, Ling, Blasberg Ronald Tumor Hypoxia Imaging. Clin. Cancer Res. 2006, 12:18-27.
20. Johnson G., et al. HL91-technetium-99m: effects of flow and hypoxia on the myocardial tissues of a new hypoxia avid imaging agent. Circulation 1995, 92(Suppl. 1):3801.
21. Jia Hong-Mei, Fang A.De-Cai., Feng A.Yan., et al. The interconversion mechanism between TcO3+ and TcO2+ core of 99mTc labeled amine-oxime (AO) complexes. Theor. Chem. Acc. 2008, 121:271-278.
22. 18F-FRP170. J. Nucl. Med. 2002, 43:109-116.
23. Liu R.S., Chou T.K., Chang C.H., Wu C.Y., Chang C.W., Chang T.J., Wang S.J., Lin W.J., Wang H.E. Biodistribution pharmacokinetics and PET imaging of [(18)F]FMISO, [(18)F]FDG and [(18)F]FAc in a sarcoma- and inflammation-bearing mouse model. Nucl. Med. Biol. 2009, 36:305-312. Apr.
24. Linder K.E., Chan Y.W., Cyr J.E., Nowotnik D.P., Eckelman W.C., Nunn A.D. Synthesis, characterization, and in vitro evaluation of nitroimidazole-BATO complexes: new technetium compounds designed for imaging hypoxic tissues. Bioconjugate Chem. 1993, 4:326-333.
25. Li Zejun, Chu Taiwei, Liu Xinqi, Wang Xiangyun Synthesis and in vitro and in vivo evaluation of three radioiodinated nitroimidazole analogues as tumor hypoxia markers. Nucl. Med. Biol. 2005, 32:225-231.
26. Ludwig Dubois, Willy Landuyt, Lieselotte Cloetens, Anne Bol, Guy Bormans, Karin Haustermans [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:209-218.
27. Martin G.V., Caldwell J.H., Graham M.M., et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J. Nucl. Med. 1992, 33:2202-2208.
28. Mannan R.H., Somayaji V.V., Lee J., Mercer J.R., Chapman J.D., Wiebe L.I. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2- nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J. Nucl. Med. 1991, 32:1764-1770.
29. Martin Gary V., Biskupiak Joseph E., Caldwell James H., Rasey Janet S., Krohn Kenneth A. Characterization of Iodovinylmisonidazole as a Marker for Myocardial Hypoxia. J. Nucl. Med. 1993, 34(6):918-924.
30. Misra Ambikanandan, Ganesh S., Shahiwala Aliasgar, et al. Drug delivery to the central nervous system: a review. J. Pharm. Pharma. Sci. 2003, 6(2):252-273.
31. Nunn A, Linder K., Strauss H.W. Nitromidazoles and imaging hypoxia. Eur. J. Nucl. Med. 1995, 22:265-280.
32. Okada Robert D., Johnson Gerald, Nguyen Kiem N., Liu Zhonglin, et al. 99mTc-HL91 "Hot Spot" Detection of Ischemic Myocardium In Vivo by Gamma Camera Imaging. Circulation 1998, 97:2557-2566.
33. Pascu Sofia I., Waghorn Philip A., et al. Designing Zn(II) and Cu(II) derivatives as probes for in vitro fluorescence imaging. Dalton Trans. 2007, 4988-4997.
34. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36:417-428.
35. Rasey J.S., Koh W.J., Grierson J.R., et al. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 1989, 17:985-991.
36. Rajendan J.G., Wilson D.C., Conrad E.U., Peterson L.M., Bruckner J.D., Rasey J.S., et al. 18FFMISO and 18FFDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:695-704.
37. Stone H.B., Brown J.M., Phillips T.L., Sutherland R.M. Oxygen in human tumors: correlation between methods of measurement and response to therapy. Radiat. Res. 1993, 136:422-434.
38. Su Zi-Fen, Zhang Xiuguo, Ballinger James R., Rauth A.M., Pollak Alfred, John R. Thornback. Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia. Bioconjugate Chem. 1999, 10:897-904.
39. Su Z.F., Ballinger J.R., Rauth A.M., Abrams D.N., Billinghurst M.W. A novel amine-dioxime chelator for technetium-99 m: synthesis and evaluation of 2-nitroimidazole-containing analogues as markers for hypoxic cells. Bioconjugate Chem. 2000, 11:652-663.
40. Schmid-Elsaesser R., Zausinger S., Hungerhuber E., Baethmann A., Reulen H.J. A critical reevaluation of the intraluminal thread model of focal cerebral ischemia: evidence of inadvertent premature reperfusion and subarachnoid hemorrhage in rats by laser-Doppler flowmetry. Stroke 1989, 29:2162-2170.
41. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 2000, 88:1474-1480.
42. Tamura A., Graham D.I., McCulloch J., Teasdale G.M. "Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion". J. Cereb. Blood Flow Metab. 1981, 1:53-60.
43. Valk PE, Mathis C.A., Prados M.D., et al. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J. Nucl. Med. 1992, 33:2133-2137.
44. Wedeking P., yost F., Wen M., Patel B., eaton S., Romero V., Linder K.E., Rumsey W., Nunn A.D. Comparison of the biologic activity of the isomers of Tc-99m-nitroimidazole complex BMS-194796. J. Nucl. Med. 1995, 36:17P.
45. Yeh K.A., Biade S., Lanciano R.M., et al. Polarographic needle electrode measurements of oxygen in rat prostate carcinomas: accuracy and reproducibility. Int. J. Radiat. Oncol. Biol. Phys. 1995, 33:111-118.
46. Yutani K, Kusuoka H, Fukuchi K, Tatsumi M, Nishimura T. Applicability of 99mTc-HL91, a putative hypoxic tracer, to detection of tumor hypoxia. J. Nucl. Med. 1999, 40:854-861.
47. 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42:417-428.
48. Zhang X., Melo T., Rauth A.M., Ballinger J.R. Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oxime. Nucl. Med. Biol. 2001, 28:949-957.